BeiGene/Novartis's Tislelizumab Faces US Delay Over China Inspection Challenges

No Timetable in Sight

 
• By Brian Yang
CHINA ZERO COVID DETERS FDA INSPECTIONS TO THE COUNTRY
BEIGENE/NOVARTIS PD-1 AGENT FACES FDA APPROVAL DELAY DUE TO CHINA'S 'COVID ZERO' POLICIES • Source: Shutterstock

More from US FDA

More from Agency Leadership